Clinical Evidence: Wegovy vs Mounjaro Side Effect Profiles
Understanding Wegovy Weight Loss Side Effects vs Mounjaro Mechanisms
The different mechanisms between Wegovy and Mounjaro directly influence their side effect profiles. Wegovy (semaglutide) works exclusively on GLP-1 receptors, while Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, potentially creating different tolerability experiences. In clinical trials, both medications showed similar gastrointestinal side effects including nausea, vomiting, and diarrhoea, though the intensity and duration may vary between individuals. The dual receptor action of Mounjaro may provide some patients with different appetite suppression patterns compared to Wegovy's single-receptor approach.
Wegovy weight loss side effects typically emerge during dose escalation phases, with most patients experiencing peak symptoms during the first 4-8 weeks of treatment. Mounjaro follows a similar pattern but with six dose levels (2.5mg to 15mg) compared to Wegovy's five doses (0.25mg to 2.4mg). This different dosing structure means the escalation timeline varies, potentially affecting when side effects occur and resolve. Both treatments require careful monitoring during the initial months as your body adapts to the appetite-regulating effects.
Wegovy vs Mounjaro Pricing and Treatment Value Comparison
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro to help you understand the investment in your weight management journey. Wegovy starter doses begin at £79.99 (0.25mg) with the maintenance dose at £209.99 (2.4mg), while Mounjaro starts at £89.99 (2.5mg) reaching £249.99 for the highest maintenance dose (15mg). Our Getting Started bundles provide convenient dose progression: Wegovy's Intro Duo (0.25mg & 0.5mg) costs £169.99, while Mounjaro's equivalent starter bundle is £179.99. New customers use code FIRST40 at checkout, while returning patients apply DOSE25 for the best prices.
The total investment varies depending on your prescribed maintenance dose and individual response to treatment. Wegovy's Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering treatment consistency without repeated ordering. Mounjaro's equivalent high-dose maintenance bundle reflects the different dosing structure but provides similar convenience benefits. Both medications are prescription-only medicines requiring clinical assessment, prescriber review, and ongoing monitoring to ensure safe and effective weight management alongside lifestyle modifications.
Clinical Evidence: Wegovy Weight Loss Side Effects from STEP Trials
The STEP clinical trial programme provides comprehensive data on Wegovy weight loss side effects experienced by patients. In STEP 1 (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity experienced nausea (44%), diarrhoea (30%), and vomiting (24%) compared to much lower rates in the placebo group. Most gastrointestinal side effects were mild to moderate and decreased over time as patients continued treatment.
STEP 5 demonstrated that Wegovy weight loss side effects remain manageable during long-term treatment, with sustained weight loss of ~15.2% at two years. The trial showed that patients who experienced initial side effects often developed tolerance, with discontinuation rates stabilising after the first six months. This evidence suggests that while early side effects are common, they typically improve with continued treatment and proper dose escalation.
How Wegovy and Mounjaro Work: Different Receptor Targets
Wegovy works as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood sugar and appetite after meals. This mechanism slows gastric emptying, promotes satiety, and reduces food cravings by acting on appetite centres in the brain. The single-receptor approach provides targeted appetite suppression but may cause predictable gastrointestinal side effects as the digestive system adapts. Mounjaro's dual GLP-1 and GIP receptor activation may provide additional metabolic benefits, though this can also influence the side effect profile differently. Both medications require weekly injection using pre-filled pens, but the different receptor targeting means individual responses can vary significantly between the two treatments.
EverydayMeds Ordering Process: From Assessment to Delivery
Our streamlined process ensures safe access to both Wegovy and Mounjaro through proper medical oversight. Complete the 3-minute online clinical assessment covering your weight management history, current health status, and treatment preferences. Our prescribers (GPhC #9012878) review your assessment within 3 working days (or 24 hours with Express Review), determining which treatment suits your individual needs. Once approved, your medication ships via temperature-controlled next-day delivery to maintain the cold-chain integrity essential for these biological medicines. Both treatments arrive with comprehensive injection guidance, dose escalation schedules, and 24/7 clinical support access. Your prescriber can adjust doses or switch treatments based on your response and any side effects experienced during the initial weeks.
Storage and Practical Differences: Wegovy vs Mounjaro
Storage requirements differ between Wegovy and Mounjaro, affecting travel and lifestyle convenience. Wegovy maintains potency for 6 weeks at room temperature below 30°C once removed from the fridge, while Mounjaro offers 21 days at room temperature. Both require refrigeration at 2-8°C before first use and should never be frozen or shaken vigorously. The FlexTouch pen system used by both medications provides easy injection, though the dose windows and clicking mechanisms vary slightly. Wegovy's dose escalation follows a 4-week schedule per dose increase, while Mounjaro typically escalates every 4 weeks but with different milligram increments. These practical differences can influence your treatment experience, especially during travel or busy periods when refrigeration access might be limited.
Comparing Wegovy Weight Loss Side Effects vs Mounjaro Tolerability
Direct comparison of Wegovy weight loss side effects versus Mounjaro requires understanding that both medications undergo different clinical trial designs, making head-to-head percentage comparisons inappropriate. However, both treatments show similar gastrointestinal side effect categories, with nausea, vomiting, and diarrhoea being most common during initial weeks. Mounjaro's dual receptor mechanism may provide some patients with different appetite suppression experiences, potentially affecting how side effects manifest or resolve.
Individual tolerance varies significantly, with some patients finding Wegovy more suitable while others prefer Mounjaro's different receptor approach. Factors influencing side effect experience include baseline metabolism, eating patterns, dose escalation speed, and concurrent medications. Both treatments are available from EverydayMeds with full prescriber support to monitor your response and adjust treatment as needed for optimal tolerability and effectiveness.
Making Your Choice: Wegovy or Mounjaro Treatment Decision
Choosing between Wegovy and Mounjaro depends on individual factors including side effect tolerance, dosing preferences, storage convenience, and cost considerations. Your EverydayMeds prescriber will evaluate your medical history, previous treatment responses, and lifestyle factors to recommend the most appropriate option. Both medications require commitment to dietary changes and increased physical activity for optimal results, with regular monitoring during the initial months. Access both treatments through our secure platform with professional clinical oversight, transparent pricing, and ongoing support throughout your weight management journey. Use discount codes FIRST40 (new customers) or DOSE25 (returning patients) applied at checkout for the best prices on either treatment option. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which prescription-only medicine suits your individual needs best.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
